Literature DB >> 29960276

Derivation and Validation of a Prediction Model for Risk Stratification of Post-Thrombotic Syndrome in Elderly Patients with a First Deep Vein Thrombosis.

Marie Méan1, Andreas Limacher2, Adriano Alatri3, Drahomir Aujesky4, Lucia Mazzolai3.   

Abstract

BACKGROUND: Not all patients carry the same risk of developing a post-thrombotic syndrome (PTS), we therefore aimed to derive a prediction rule for risk stratification of PTS in patients with deep vein thrombosis (DVT).
METHODS: Our derivation sample included 276 patients with a first acute symptomatic lower limb DVT enrolled in a prospective cohort. We derived our prediction rule using regression analysis, with the occurrence of PTS within 24 months of a DVT based on the Villalta score as outcome, and 11 candidate variables as predictors. We used bootstrapping methods for internal validation.
RESULTS: Overall, 161 patients (58.3%) developed a PTS within 24 months of a DVT. Our prediction rule was based on five predictors (age ≥ 75 years, prior varicose vein surgery, multi-level thrombosis, concomitant antiplatelet/non-steroidal anti-inflammatory drug therapy and the number of leg symptoms and signs). Overall, 16.3, 31.2 and 52.5% of patients were classified as low- (score, 0-3), moderate (score, 4-5) and high-risk (score, ≥ 6), for developing a PTS. Within 24 months of the index DVT, 24.4% of the patients in the low-risk category developed a PTS, 38.4% in the moderate and 80.7% in the high-risk category. The prediction model showed good predictive accuracy (area under the curve, 0.77; 95% confidence interval, 0.71-0.82, calibration slope, 0.90 and Brier score, 0.20).
CONCLUSION: This easy-to-use clinical prediction rule accurately identifies patients with DVT who are at high risk of developing PTS within 24 months who could potentially benefit from special educational or therapeutic measures to limit the risk of PTS. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2018        PMID: 29960276     DOI: 10.1055/s-0038-1661392

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  Thrombolytic therapy in acute venous thromboembolism.

Authors:  Thita Chiasakul; Kenneth A Bauer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

2.  Evidence-Based Nursing Model in Interventional Thrombolysis for Acute Lower Extremity Arterial Embolism.

Authors:  Meijuan Yang; Lijiao Chen; Min Zhang; Xiaoling Huang; Wenjun Zhao; Hui Wang
Journal:  Contrast Media Mol Imaging       Date:  2022-05-25       Impact factor: 3.009

3.  Preventive Effect of Intensive Nursing Intervention of Deep Vein Thrombosis of Lower Extremities in Elderly Patients with Gastrointestinal Tumors after Surgery.

Authors:  Yan Li; Fei Xiao
Journal:  J Oncol       Date:  2022-04-26       Impact factor: 4.501

4.  External validation of the SOX-PTS score in a prospective multicenter trial of patients with proximal deep vein thrombosis.

Authors:  Anat Rabinovich; Chu-Shu Gu; Suresh Vedantham; Clive Kearon; Samuel Z Goldhaber; Heather L Gornik; Susan R Kahn
Journal:  J Thromb Haemost       Date:  2020-04-09       Impact factor: 5.824

5.  A predictive model for postthrombotic syndrome in proximal deep vein thrombosis patients.

Authors:  Peng Qiu; Junchao Liu; Fuzhen Wan; Yuqian Chen; Kaichuang Ye; Jinbao Qin; Qun Huang; Xinwu Lu
Journal:  Ann Transl Med       Date:  2021-04

6.  A Prediction Model Based on Blood Biomarker for Mortality Risk in Patients with Acute Venous Thromboembolism.

Authors:  Jianjun Jiang; Junshuai Xue; Yang Liu
Journal:  J Inflamm Res       Date:  2022-08-18

7.  Machine learning-based prediction of the post-thrombotic syndrome: Model development and validation study.

Authors:  Tao Yu; Runnan Shen; Guochang You; Lin Lv; Shimao Kang; Xiaoyan Wang; Jiatang Xu; Dongxi Zhu; Zuqi Xia; Junmeng Zheng; Kai Huang
Journal:  Front Cardiovasc Med       Date:  2022-09-16

Review 8.  Prevention and Management of the Post-Thrombotic Syndrome.

Authors:  Ilia Makedonov; Susan R Kahn; Jean-Philippe Galanaud
Journal:  J Clin Med       Date:  2020-03-27       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.